Evidence map›Paper›PMID 32970730›Full record

ArticlePloS one2020

Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.

Collins Iwuji, Rujeko Samanthia Chimukuche, Thembelihle Zuma, Melanie Plazy, Joseph Larmarange, Joanna Orne-Gliemann, Mark Siedner, Maryam Shahmanesh, Janet Seeley

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01509508 (A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01509508 nacompletednot on this map

A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2012 to 2016Enrolled28,153ConditionsHIV InfectionArmsImmediate ARV treatment initiation with TDF/FTC/EFV, South African recommendation guided ARV (TDF/FTC/EFV) initiation
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Collins IwujiDepartment of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, United Kingdom.ORCID 0000-0003-2045-1717
Rujeko Samanthia ChimukucheAfrica Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Thembelihle ZumaAfrica Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Melanie PlazyUniv. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.
Joseph LarmarangeInstitut de Recherche pour le Développement(IRD), Centre Population et Développement (Ceped), Paris, France.ORCID 0000-0001-7097-700X
Joanna Orne-GliemannUniv. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.
Mark SiednerAfrica Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Maryam ShahmaneshAfrica Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Janet SeeleyAfrica Health Research Institute, Berea, KwaZulu-Natal, South Africa.
Africa Health Research Institute · ZAUniversité de Bordeaux · FRBrighton and Sussex Medical School · GBCentre Population et Développement · FRHarvard University · USLondon School of Hygiene & Tropical Medicine · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionAntiretroviral therapy (ART) has revolutionised the care of HIV-positive individuals resulting in marked decreases in morbidity and mortality, and markedly reduced transmission to sexual partners. However, these benefits can only be realised if individuals are aware of their HIV-positive status, initiated and retained on suppressive lifelong ART. Framed using the socio-ecological model, the present study explores factors contributing to poor ART uptake among community members despite high acceptance of HIV-testing within a Treatment as Prevention (TasP) trial. In this paper we identify barriers and facilitators to treatment across different levels of the socio-ecological framework covering individual, community and health system components.

methodsThis research was embedded within a cluster-randomised trial (ClinicalTrials.gov, number NCT01509508) of HIV treatment as Prevention in rural KwaZulu-Natal, South Africa. Data were collected between January 2013 and July 2014 from resident community members. Ten participants contributed to repeat in-depth interviews whilst 42 participants took part in repeat focus group discussions. Data from individual interviews and focus group discussions were triangulated using community walks to give insights into community members' perception of the barriers and facilitators of ART uptake. We used thematic analysis guided by a socio-ecological framework to analyse participants' narratives from both individual interviews and focus group discussions.

resultsBarriers and facilitators operating at the individual, community and health system levels influence ART uptake. Stigma was an over-arching barrier, across all three levels and expressed variably as fear of HIV disclosure, concerns about segregated HIV clinical services and negative community religious perceptions. Other barriers were individual (substance misuse, fear of ART side effects), community (alternative health beliefs). Facilitators cited by participants included individual (expectations of improved health and longer life expectancy following ART, single tablet regimens), community (availability of ART in the community through mobile trial facilities) and health system factors (fast and efficient service provided by friendly staff). DISCUSSION: We identified multiple barriers to achieving universal ART uptake. To enhance uptake in HIV care services, and achieve the full benefits of ART requires interventions that tackle persistent HIV stigma, and offer people with HIV respectful, convenient and efficient services. These interventions require evaluation in appropriately designed studies.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveFemaleFocus GroupsHealth Services AccessibilityHIV InfectionsHumansMaleMass ScreeningQualitative ResearchRural PopulationSexual PartnersSocial StigmaSouth AfricaAnti-HIV Agents

Identifiers

PMID32970730
PMCPMC7514038
OpenAlexW3087801212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.